Innovation and Technology Spotlight: Artificial Intelligence for Drug Discovery
This spotlight explores the emerging role of artificial intelligence (AI) in drug discovery and examines Canada’s position within this rapidly evolving field. The study is based on a series of interviews and a literature review.
Could AI for drug discovery offer Canada an upstream specialization in global life sciences despite the absence of a Canadian-headquartered pharmaceutical giant? Is AI improving the economics of discovery, shortening timelines, reducing exploratory costs, and creating more viable opportunities before expensive clinical development? Are Canadian firms generating valuable intellectual property, platforms, and partnerships? What did interviewees identify as Canada’s most urgent bottleneck? And are there opportunities from shifting policy and capital to supporting strategic scale-up, concentrating support on high-potential firms, strengthening retention pathways, and focusing on recycling exit gains?
Check out the spotlight for more details.
Highlights
About the Innovation and Technology Spotlight Series
How AI changes the drug discovery equation
Canada’s comparative advantage
An advantage at risk
Discovering value
Questions for Canadian policy-makers
Appendix A: Methodology
Appendix B: Bibliography
